New York, NY Hospira, Inc., a Pfizer company, has announced the voluntary recall of several injectable medications due to the risk of glass particulate contamination. This precautionary measure aims to safeguard patients from potential severe health complications, including the risk of blood clots.
The recall follows the discovery of glass particles in some batches of injectable drugs during routine product inspection. The affected medications, including key products like Sodium Bicarbonate and Atropine Sulfate injections, are commonly used in medical treatments. The presence of glass particles in these injections poses a significant health hazard. If administered, these contaminants can lead to critical health issues, ranging from vein inflammation and granuloma to potentially life-threatening blood clot events.
As of now, Hospira has not received reports of any incidents or adverse reactions related to this recall. However, the company is taking all necessary steps to mitigate risks and ensure patient safety. Healthcare professionals have been advised to stop using the affected lots immediately and to follow the recommended protocols for reporting any health complications potentially linked to these products.
The products recalled by Hospira, Inc., a Pfizer company, include:
- 4.2% Sodium Bicarbonate Injection, USP ABBOJECT® Glass Syringe, 5 mEq/10 mL
- 8.4% Sodium Bicarbonate Injection, USP Lifeshield® ABBOJECT® Glass Syringe, 50 mEq/50 mL
- Atropine Sulfate Injection, USP Lifeshield® ABBOJECT® Glass Syringe, 1 mg/10 mL
